Does bilirubin prevent hepatic steatosis through activation of the PPAR alpha nuclear receptor?

作者：Hinds Terry D Jr; Adeosun Samuel O; Alamodi Abdulhadi A; Stec David E

来源：Medical Hypotheses, 2016, 95: 54-57.

DOI：10.1016/j.mehy.2016.08.013

• Heme oxygenase
• Bilirubin
• Biliverdin
• NAFLD
• NASH
• Non-alcoholic fatty liver disease
• PPAR
• PPAR alpha
• SPPARM
• Nuclear receptors

Several large population studies have demonstrated a negative correlation between serum bilirubin levels and the development of obesity, hepatic steatosis, and cardiovascular disease. Despite the strong correlative data demonstrating the protective role of bilirubin, the mechanism by which bilirubin can protect against these pathologies remains unknown. Bilirubin has long been known as a powerful antioxidant and also has anti-inflammatory actions, each of which may contribute to the protection afforded by increased levels. We have recently described a novel function of bilirubin as a ligand for the peroxisome proliferator-activated receptor-alpha (PPAR alpha), which we show specifically binds to the nuclear receptor. Bilirubin may function as a selective PPAR modulator (SPPARM) to control lipid accumulation and blood glucose. However, it is not known to what degree bilirubin activation of PPAR alpha is responsible for the protection afforded to reduce hepatic steatosis. We hypothesize that bilirubin, acting as a novel SPPARM, increases hepatic fatty acid metabolism through a PPAR alpha-dependent mechanism which reduces hepatic lipid accumulation and protects against hepatic steatosis and non-alcoholic fatty liver disease (NAFLD).

• 出版日期2016-10